In a groundbreaking achievement for global public health, scientists have developed a revolutionary antivenom capable of neutralizing the venom of 19 of the world’s most dangerous snakes. This includes notorious species such as the black mamba, king cobra, and tiger snake.
The new antidote, made possible through an innovative combination of advanced antibodies and a small molecule inhibitor, has the potential to transform the treatment of snakebites worldwide and paves the way for a universal antivenom that could save countless lives.
A Century-Old Process Finally Gets an Upgrade
For more than 100 years, the production of antivenom has remained relatively unchanged. The traditional method involves injecting animals like horses or sheep with venom from a specific snake species. These animals then produce antibodies to counteract the venom, which are harvested and used to create antivenoms.
While effective in many cases, this system comes with limitations. Treatments tend to be species- or region-specific, meaning a person bitten by a snake in one part of the world may not benefit from antivenom produced elsewhere. Additionally, these treatments can cause adverse reactions because they introduce non-human antibodies into the patient’s body.
The need for a broader, more universally applicable solution has long been clear to researchers, particularly in regions where access to appropriate antivenom is limited. With over a million snakebites occurring annually across the globe—many of them fatal or resulting in permanent disability—an innovative approach was overdue.
The Unlikely Key: A Man with “Hyper-Immunity”
In the search for a better way, American researchers encountered an extraordinary individual whose unique personal experiment with snake venom opened a new frontier in antivenom science. Tim Friede, a self-described snakebite enthusiast, had voluntarily exposed himself to the venom of numerous deadly snake species over the course of nearly two decades.
“The donor, for a period of nearly 18 years, had undertaken hundreds of bites and self-immunizations with escalating doses from 16 species of very lethal snakes that would normally kill a horse,” explained study first author Dr. Jacob Glanville, CEO of Centivax Inc, based in California.
Friede’s daring and controversial practice had granted him what scientists referred to as “hyper-immunity” to a range of snake neurotoxins. When he agreed to participate in the study, researchers quickly realized his blood contained an extremely valuable resource: antibodies capable of neutralizing multiple types of venom at once.
“What was exciting about the donor was his once-in-a-lifetime unique immune history,” said Dr. Glanville in a media release.
“Not only did he potentially create these broadly neutralizing antibodies, it could give rise to a broad-spectrum or universal antivenom,” he added.
Building a Universal Antivenom: The Method Behind the Discovery
To test the feasibility of creating a universal antivenom, the research team designed an experiment using a panel of 19 snake species, carefully selected from the World Health Organization’s category 1 and 2 deadliest snakes. This group represented nearly half of all known venomous snake species and included infamous names like coral snakes, mambas, cobras, taipans, and kraits.
Blood samples were drawn from Friede, and the scientists isolated antibodies that reacted with neurotoxins from the tested snake venoms. The next step was to assess how effective these antibodies would be in neutralizing venom in live test models.
One by one, the antibodies were administered to mice that had been envenomed with lethal doses from each of the 19 species. By observing the outcomes, the researchers were able to identify which antibodies were effective, and which combinations might provide the most comprehensive protection.
The Three-Part Antidote Cocktail
Through this systematic testing, the scientists developed a three-part antidote cocktail made up of two antibodies from the donor’s blood and a small molecule known for its venom-neutralizing properties. The first antibody, called LNX-D09, demonstrated its power by protecting mice from lethal doses of venom from six of the snake species.
To broaden the cocktail’s effectiveness, the team introduced varespladib, a small molecule already known to inhibit certain snake toxins. This addition expanded protection to cover three more species. The final key was the second donor-derived antibody, SNX-B03, which completed the protective barrier against all 19 snakes in the test panel.
“By the time we reached three components, we had a dramatically unparalleled breadth of full protection for 13 of the 19 species and then partial protection for the remaining that we looked at,” explained Glanville. “We were looking down at our list and thought, ‘what’s that fourth agent?’ And if we could neutralize that, do we get further protection?”
Though a fourth agent wasn’t added, the three-component mixture proved so effective that the researchers believe it could potentially work against other venomous species not included in the initial study.
Next Steps: From Mice to the Real World
Having achieved promising results in animal models, the next phase involves testing the antivenom in practical, real-world scenarios. The team plans to start by treating dogs in veterinary clinics in Australia that have suffered snakebites. These cases offer a valuable opportunity to further refine the antivenom before broader human clinical trials.
The researchers also have plans to develop a complementary antivenom targeting viper species, another major snake family responsible for numerous deaths and injuries worldwide.
“We’re turning the crank now, setting up reagents to go through this iterative process of saying what’s the minimum sufficient cocktail to provide broad protection against venom from the viperids,” said Professor Peter Kwong of Columbia University, the study’s lead author.
“The final contemplated product would be a single, pan-antivenom cocktail or we potentially would make two: one that is for the elapids and another that is for the viperids because some areas of the world only have one or the other.”
Funding and the Future of Snakebite Treatment
The ambitious research project has attracted significant financial backing, with funding from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, the National Institutes of Health Small Business Innovation Research program, and the US Department of Energy.
The team is now seeking further support from governments, philanthropic foundations, and pharmaceutical companies to move toward large-scale manufacturing and clinical deployment.
If successful, this antivenom could redefine how the medical world handles snakebites, saving lives in regions where timely and species-specific treatments are currently unavailable. This remarkable scientific collaboration might finally bring an end to one of the oldest and deadliest natural hazards humanity has faced.
Recommended For You
